Johnson & Johnson (NYSE:JNJ) Position Increased by Sabal Trust CO

Sabal Trust CO increased its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 1.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,131 shares of the company's stock after purchasing an additional 2,176 shares during the period. Johnson & Johnson accounts for 1.9% of Sabal Trust CO's portfolio, making the stock its 13th largest position. Sabal Trust CO's holdings in Johnson & Johnson were worth $33,853,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. Creative Financial Designs Inc. ADV lifted its holdings in shares of Johnson & Johnson by 16.2% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 11,049 shares of the company's stock worth $1,832,000 after purchasing an additional 1,540 shares during the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Johnson & Johnson by 9.1% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 1,780,024 shares of the company's stock worth $295,199,000 after purchasing an additional 148,818 shares during the last quarter. Aspetuck Financial Management LLC bought a new stake in shares of Johnson & Johnson in the 1st quarter worth approximately $566,000. Pure Financial Advisors LLC lifted its holdings in shares of Johnson & Johnson by 14.1% in the 1st quarter. Pure Financial Advisors LLC now owns 19,897 shares of the company's stock worth $3,300,000 after purchasing an additional 2,466 shares during the last quarter. Finally, Phillips Wealth Planners LLC increased its position in Johnson & Johnson by 39.1% in the 1st quarter. Phillips Wealth Planners LLC now owns 4,857 shares of the company's stock valued at $737,000 after acquiring an additional 1,366 shares during the period. Institutional investors own 69.55% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently commented on JNJ shares. Royal Bank Of Canada restated an "outperform" rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Thursday, June 5th. Guggenheim restated a "neutral" rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Raymond James Financial lowered their target price on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research report on Monday, April 14th. Finally, Bank of America lowered their target price on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Stock Up 0.3%

Shares of JNJ stock opened at $152.44 on Friday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The stock has a market cap of $366.78 billion, a PE ratio of 16.96, a price-to-earnings-growth ratio of 2.30 and a beta of 0.42. The business's fifty day moving average is $153.75 and its 200-day moving average is $153.71. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.03 and a current ratio of 1.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were paid a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.